Mylan inks deal with Biocon for insulin analogs but preps for more in India?
This article was originally published in Scrip
Executive Summary
Mylan, the world's third largest generics and specialty pharmaceutical company, is upping its engagement with Indian firms. It has entered into a collaboration with Biocon, India's largest biotechnology company by revenue, to develop and commercialize generic versions of three insulin analog products, amid talk that it may also be keen to snap up a formulations plant.
You may also be interested in...
Riding The Next Wave Of Biosimilars: Sandoz To Link Up With India's Biocon
Pooling resources appears key to a major new collaboration in the biosimilars space, between Sandoz and India's Biocon, to develop the next generation of biosimilar immunology and oncology products.
Riding The Next Wave Of Biosimilars: Sandoz To Link Up With India's Biocon
Pooling resources appears key to a major new collaboration in the biosimilars space, between Sandoz and India's Biocon, to develop the next generation of biosimilar immunology and oncology products.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.